Syncardia’s growth potential and exit strategy are discussed. The 13 pound Freedom Driver which is approved in Europe and is expecting FDA approval in June, and would allow patients unprecented mobility and would greatly expand adoption of the device. Along with approval of the portable driver, SynCardia expects to reach two more milestones this year: FDA permission to test an artificial heart small enough for women and teenagers, and approval to use its heart as “destination therapy” – a more permanent solution for patients who don’t qualify for transplants because of age or illness. Together, the approvals will set the stage for SynCardia to grow – and perhaps attract a deep-pocket buyer.
Read More: Syncardia a heartbeat from leadership role